 Shares of Madrigal Pharmaceuticals Inc. MDGL, 1.43 soared 209.6 in premarket trading on Monday after the company shared positive data from a pivotal Phase 3 clinical trial assessing its experimental treatment for nonalcoholic steatohepatitis NASH with liver fibrosis. Madrigal said it is aiming to get an accelerated approval for the drug, resmetirom. 